Core Viewpoint - The company, Da An Gene, has recently obtained a medical device registration certificate for its MTHFR gene typing detection kit, which enhances its product portfolio and expands application areas [1] Group 1 - The registration certificate was issued by the National Medical Products Administration, with the certificate number being 国械注准20253401571 [1] - The effective period of the registration certificate is from the date of approval until August 13, 2030 [1] - The kit is designed for in vitro qualitative detection of the polymorphism at the C677T site of the MTHFR gene in genomic DNA from human whole blood samples [1] Group 2 - The acquisition of this registration certificate enriches the company's product offerings [1] - The product is currently in the market development stage, indicating that market demand remains uncertain [1]

证券代码：002030 证券简称：达安基因 公告编号：2025-041 广州达安基因股份有限公司 关于取得一个医疗器械注册证的提示性公告 特此公告。 广州达安基因股份有限公司 董 事 会 2025 年 8 月 15 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，广州达安基因股份有限公司（以下简称"公司"）取得国家药品监督管 理局颁发的医疗器械注册证一个，具体为： 医疗器械名称：人类 MTHFR 基因分型检测试剂盒（PCR-荧光探针法），注 册证编号：国械注准 20253401571。有效期自批准之日起至 2030 年 8 月 13 日。 预期用途：本试剂盒适用于体外定性检测人全血样本基因组 DNA 中 5,10-亚甲基 四氢叶酸还原酶（MTHFR）基因 C677T 位点的多态性。 上述医疗器械注册证的取得丰富了公司的产品组合，拓宽了公司产品的应用 领域。目前，上述产品尚处于市场开发阶段，市场需求存在不确定性，请广大投 资者注意投资风险。 ...

Group 1 - Multiple listed companies are developing detection solutions for Chikungunya virus, including Kingmed Diagnostics, Wanfu Biology, and Shengxiang Biology [1][2] - Kingmed Diagnostics has established a comprehensive platform for serological, fluorescent PCR, and sequencing tests to accurately identify the Chikungunya virus, aiding in clinical diagnosis [1] - Wanfu Biology has responded to the recent guidelines from the National Disease Control Bureau by developing several detection products that create a closed-loop system for rapid screening, precise detection, and monitoring [1] - Shengxiang Biology has introduced a dual-platform solution combining rapid nucleic acid testing and sequencing for precise tracing, with a detection time of 25 to 45 minutes and high sensitivity [1] Group 2 - According to a report by Everbright Securities, several domestic listed companies, including Da'an Gene, Wanfu Biology, Shengxiang Biology, Zhijiang Biology, Shuoshi Biology, Mingde Biology, and Rendu Biology, have launched Chikungunya virus detection solutions [2]

Core Viewpoint - The company, Da'an Gene, stated that as of July 31, 2025, the total number of shareholders is expected to be approximately 158,000 [1] Summary by Relevant Sections - Shareholder Information - The company anticipates having around 158,000 shareholders by the end of July 2025 [1]

Market Overview - The precision medicine sector experienced a decline of 1.18% on August 1, with WuXi AppTec leading the drop [1] - The Shanghai Composite Index closed at 3559.95, down 0.37%, while the Shenzhen Component Index closed at 10991.32, down 0.17% [1] Stock Performance - Notable gainers in the precision medicine sector included: - Ruian Gene (688217) with a closing price of 30.34, up 5.38% [1] - Da An Gene (002030) at 7.18, up 3.01% [1] - New Open Source (300109) at 17.03, up 2.34% [1] - Conversely, major decliners included: - WuXi AppTec (603259) at 93.00, down 3.40% [2] - Anke Bio (300009) at 11.90, down 1.73% [2] - Zhongyuan Union (600645) at 26.10, down 1.51% [2] Capital Flow - The precision medicine sector saw a net outflow of 993 million yuan from institutional investors, while retail investors contributed a net inflow of 668 million yuan [2][3] - The capital flow for specific stocks showed: - Da An Gene (002030) had a net inflow of 46.97 million yuan from institutional investors [3] - WuXi AppTec (603259) experienced a net outflow of 83.98 million yuan [2][3]

Group 1 - The company has a collaborative research project with Sun Yat-sen University and maintains a good relationship with the institution [1] - The main products of the company include PCR diagnostic reagents, related consumables, and instruments, with no involvement in drug-related business [1] - The company emphasizes market value management, although its stock price is influenced by macroeconomic factors, industry cycles, and market sentiment [1]

Group 1 - The hepatitis concept sector experienced a short-term surge, with Kewah Bio (002022) hitting the daily limit up [1] - Other companies such as Qianyuan Pharmaceutical (300254), Hendi Pharmaceutical (301211), Da'an Gene (002030), Asia-Pacific Pharmaceutical (002370), and Kangzhi Pharmaceutical (300086) also saw significant increases in their stock prices [1]

Core Viewpoint - The article discusses the outbreak of Chikungunya fever in China and globally, highlighting the urgent need for effective detection and prevention measures due to the lack of specific treatments and vaccines [2][3]. Group 1: Current Situation - As of July 23, 2025, Foshan reported a total of 3,645 confirmed cases of Chikungunya fever, with the Shunde District accounting for 3,317 cases, an increase of 383 cases from the previous day [2]. - The World Health Organization (WHO) has warned that 119 countries and regions are experiencing virus transmission, with approximately 5.5 million people at risk of infection, potentially straining healthcare systems [2]. Group 2: Prevention and Control - There are currently no specific drugs or vaccines for Chikungunya fever; the primary prevention strategy is mosquito control, including eliminating breeding sites and using personal protective measures [3]. - The clinical features of Chikungunya fever include acute fever, severe joint pain, and rash, with higher risks for children, the elderly, and immunocompromised individuals [3]. Group 3: Diagnostic Methods - Common diagnostic methods for Chikungunya fever include serological testing, nucleic acid testing, and virus isolation, with specific timelines for sample collection to ensure accurate results [4]. - Currently, there are no approved test kits for Chikungunya fever in China, which poses a challenge for timely diagnosis [4]. Group 4: Market Opportunities - Several domestic companies, including DaAn Gene, Wanfu Biology, and Shengxiang Biology, are developing Chikungunya fever detection solutions based on PCR methodologies, with others exploring high-throughput sequencing and antigen-antibody detection methods [5]. - The ongoing outbreak is expected to accelerate the accumulation of clinical data for these detection products, potentially speeding up their approval and market entry [5].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [4]. Core Insights - The number of confirmed cases of Chikungunya fever is rapidly increasing, with 3,645 cases reported in Foshan as of July 23, 2025, including a daily increase of 383 cases in Shunde District [1]. - The World Health Organization (WHO) has warned that 119 countries and regions are at risk of virus transmission, with approximately 5.5 million people facing infection risk [1]. - There are currently no specific drugs or vaccines available for Chikungunya fever, making mosquito control the primary prevention strategy [2]. - Multiple companies have launched testing solutions for Chikungunya fever, and the approval of these products is expected to accelerate [3]. Summary by Sections Industry Overview - Chikungunya fever is caused by the Chikungunya virus (CHIKV) and primarily transmitted by Aedes mosquitoes, with symptoms including acute fever and severe joint pain [2]. - The absence of effective treatment and vaccines necessitates supportive care and preventive measures such as mosquito control [2]. Testing Solutions - Common testing methods for Chikungunya fever include serological testing, nucleic acid testing, and virus isolation, but no test kits have been approved for sale in China [2]. - Companies like DaAn Gene, Wanfu Biology, and others have developed PCR-based testing solutions, while others are exploring high-throughput sequencing methods [3]. Investment Opportunities - The report suggests focusing on companies that have developed Chikungunya testing solutions, including DaAn Gene, Wanfu Biology, and others [3].

Core Viewpoint - The epidemic of Chikungunya fever in Guangdong Province remains at a high plateau, indicating a severe situation that requires attention [1]. Summary by Sections Epidemic Situation - As of July 22, 2025, Shunde District in Foshan City reported a total of 2,934 confirmed cases of Chikungunya fever, with a significant increase of 463 cases in just one day [4][5]. - The first report of the epidemic in Shunde was on July 15, 2025, with 478 confirmed cases, showing an increase of over 2,000 cases in just over a week [4]. - The World Health Organization (WHO) reported that 119 countries and regions have identified Chikungunya virus transmission, with approximately 5.5 million people at risk globally, potentially leading to widespread outbreaks [4][5]. Companies Involved in Prevention and Detection - **Runben Co., Ltd. (润本股份)**: A leading domestic company in mosquito repellent products, with a revenue of 440 million yuan in 2024, showing a year-on-year growth of 35.4% and a gross margin of 54.2% [7]. - **Rainbow Group (彩虹集团)**: A well-known pest control company in China, offering a full range of mosquito repellent products that play a crucial role in controlling Chikungunya fever [8]. - **Shanghai Jahwa (上海家化)**: The "Liushen" brand is the top brand in China for mosquito repellent flower water, holding significant brand influence in mosquito prevention and personal care [9]. - **Longyun Group (朗云集团)**: A Hong Kong-listed company that has maintained the number one market share in pest control products for ten consecutive years, with notable products performing well during the epidemic [10]. - **Kangzhi Pharmaceutical (康芝药业)**: Offers a full range of baby and child health protection products, including disinfectants and mosquito repellents, demonstrating expertise in child health protection [11]. - **Shuoshi Gene (硕世纪录物)**: Utilizes gene sequencing technology for Chikungunya fever testing, providing precise diagnostic support for epidemic prevention [12]. - **Da'an Gene (达安基因)**: Provides nucleic acid testing kits for Chikungunya virus, leveraging extensive experience in molecular diagnostics [13]. - **Huiyu Medical (会域医学)**: A leading medical testing institution in China, employing advanced technology for accurate diagnosis of Chikungunya fever [14]. - **Wansheng Biology (万学生物)**: Offers rapid testing solutions for Chikungunya virus, focusing on point-of-care testing [16]. - **Nuo Weisha (诺唯莎)**: Combines molecular design with various heat-start technologies to enhance detection efficiency for mosquito-borne viruses [17].